| Independent assessment of candidate HIV incidence assays on specimens in the CEPHIA repository R Kassanjee, CD Pilcher, SM Keating, SN Facente, E McKinney, MA Price, ... AIDS (London, England) 28 (16), 2439, 2014 | 166 | 2014 |
| Sowing the seeds for sustainable change: a community-based participatory research partnership for health promotion in Indiana, USA and its aftermath M Minkler, VB Vásquez, JR Warner, H Steussey, S Facente Health Promotion International 21 (4), 293-300, 2006 | 111 | 2006 |
| Addressing food security through public policy action in a community-based participatory research partnership V Breckwich Vásquez, D Lanza, S Hennessey-Lavery, S Facente, ... Health Promotion Practice 8 (4), 342-349, 2007 | 107 | 2007 |
| Post-marketing surveillance of OraQuick whole blood and oral fluid rapid HIV testing LG Wesolowski, DA MacKellar, SN Facente, T Dowling, SF Ethridge, ... Aids 20 (12), 1661-1666, 2006 | 105 | 2006 |
| Viral load criteria and threshold optimization to improve HIV incidence assay characteristics-a CEPHIA analysis R Kassanjee, CD Pilcher, MP Busch, G Murphy, SN Facente, SM Keating, ... AIDS (London, England) 30 (15), 2361, 2016 | 94 | 2016 |
| Performance of rapid point-of-care and laboratory tests for acute and established HIV infection in San Francisco CD Pilcher, B Louie, S Facente, S Keating, J Hackett Jr, A Vallari, C Hall, ... PloS one 8 (12), e80629, 2013 | 77 | 2013 |
| HIV antibody level as a marker of HIV persistence and low-level viral replication SM Keating, CD Pilcher, V Jain, M Lebedeva, D Hampton, ... The Journal of infectious diseases 216 (1), 72-81, 2017 | 53 | 2017 |
| Community-based participatory research in disability and long-term care policy: A case study M Minkler, J Hammel, CJ Gill, S Magasi, V Breckwich Vásquez, M Bristo, ... Journal of Disability Policy Studies 19 (2), 114-126, 2008 | 41 | 2008 |
| Fluvoxamine for the early treatment of SARS-CoV-2 infection: a review of current evidence SN Facente, AM Reiersen, EJ Lenze, DR Boulware, JD Klausner Drugs 81 (18), 2081-2089, 2021 | 40 | 2021 |
| Moving towards a reliable HIV incidence test–current status, resources available, future directions and challenges ahead G Murphy, CD Pilcher, SM Keating, R Kassanjee, SN Facente, A Welte, ... Epidemiology & Infection 145 (5), 925-941, 2017 | 39 | 2017 |
| Interpreting HIV diagnostic histories into infection time estimates: analytical framework and online tool E Grebe, SN Facente, J Bingham, CD Pilcher, A Powrie, J Gerber, ... BMC infectious diseases 19 (1), 1-10, 2019 | 37 | 2019 |
| False positive rate of rapid oral fluid HIV tests increases as kits near expiration date SN Facente, T Dowling, E Vittinghoff, DL Sykes, GN Colfax PloS one 4 (12), e8217, 2009 | 34 | 2009 |
| Estimated hepatitis C prevalence and key population sizes in San Francisco: a foundation for elimination SN Facente, E Grebe, K Burk, MD Morris, EL Murphy, A Mirzazadeh, ... PloS one 13 (4), e0195575, 2018 | 33 | 2018 |
| Performance of the Bio-Rad Geenius HIV1/2 supplemental assay in detecting “recent” HIV infection and calculating population incidence SM Keating, R Kassanjee, M Lebedeva, SN Facente, JC MacArthur, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 73 (5), 581-588, 2016 | 31 | 2016 |
| Performance of risk-based criteria for targeting acute HIV screening in San Francisco SN Facente, CD Pilcher, WE Hartogensis, JD Klausner, SS Philip, B Louie, ... PLoS One 6 (7), e21813, 2011 | 29 | 2011 |
| New treatments have changed the game: hepatitis C treatment in primary care SN Facente, K Burk, K Eagen, ES Mara, AA Smith, CS Lynch Infectious Disease Clinics 32 (2), 313-322, 2018 | 28 | 2018 |
| Feasibility and effectiveness of daily temperature screening to detect COVID-19 in a prospective cohort at a large public university SN Facente, LA Hunter, LJ Packel, Y Li, A Harte, G Nicolette, S McDevitt, ... BMC Public Health 21 (1), 1-10, 2021 | 25 | 2021 |
| Infection staging and incidence surveillance applications of high dynamic range diagnostic immuno-assay platforms E Grebe, A Welte, J Hall, SM Keating, SN Facente, K Marson, JN Martin, ... JAIDS Journal of Acquired Immune Deficiency Syndromes 76 (5), 547-555, 2017 | 25 | 2017 |
| Performance comparison of the Maxim and Sedia Limiting Antigen Avidity assays for HIV incidence surveillance JB Sempa, A Welte, MP Busch, J Hall, D Hampton, SN Facente, ... PloS one 14 (7), e0220345, 2019 | 23 | 2019 |
| Comparison of cross-sectional HIV incidence assay results from dried blood spots and plasma KE Schlusser, C Pilcher, EG Kallas, BR Santos, SG Deeks, S Facente, ... PLoS One 12 (2), e0172283, 2017 | 23 | 2017 |
